Tuberculosis Clinical Trial
Official title:
A Phase II Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Children and Infants After BCG Vaccination at Birth
This study is designed to evaluate the safety of the TB vaccine MVA85A in healthy children
and infants in South Africa. A single vaccination with MVA85A has been shown to be safe and
highly immunogenic in a wide range of subjects in previous clinical trials. In this trial,we
will vaccinate 24 children with 5 x 10^7pfu of MVA85A and three groups of 36 infants with
2.5 x 10^7, 5 x 10^7 or 1 x 10^8 pfu.
Participants will be identified from the general population living in Worcester, Western
Cape, South Africa
M.tb is an intracellular organism and protective immunity is dependent on an intact cellular
immune system. Both Class II-restricted CD4+ and Class I-restricted CD8+ T lymphocytes are
important for protection. Gamma delta cells and non-classically restricted T cells such as
CD1-restricted T cells may also play a protective role but knowledge of how to induce these
to protective levels by vaccination is very limited. Although several vaccine delivery
systems are capable of inducing T cells, e.g. protein/adjuvant combinations, DNA vaccines
and recombinant viral vectors, when used alone these delivery systems induce only low-level
responses. Heterologous prime-boost immunisation strategies involve immunizing with 2 two
different vaccines, each expressing the same antigen, several weeks apart. These strategies
induce higher levels of CD4+ and CD8+ T cells than homologous boosting in animal models of
malaria, HIV and TB.
Recombinant modified vaccinia virus Ankara expressing antigen 85A (MVA85A). When used in
heterologous prime-boost strategies, some viral vectors are very good at boosting previously
primed T cell responses, particularly recombinant adenoviral constructs and recombinant pox
viruses. Modified vaccinia virus Ankara (MVA) is an attenuated strain of vaccinia virus that
has been passaged more than 500 times through chick embryo fibroblasts and as a consequence
has lost both host range genes and cytokine receptor genes. MVA has an excellent safety
record, as it was used to vaccinate more than 120,000 people at the end of the smallpox
eradication campaign, with no serious adverse events. In humans, several hundred HIV
negative volunteers have now been immunized with recombinant MVAs expressing a number of
different antigens, with no serious adverse events. A recombinant MVA expressing an antigen
from Plasmodium falciparum has been demonstrated to boost CD4+ and CD8+ T cells in humans.
Recombinant MVAs are now in clinical trials for several infectious diseases including HIV,
hepatitis B and malaria. Importantly, for a new TB vaccine, the safety of MVA as a viral
vector has now been demonstrated in HIV positive patients.
Including BCG in such heterologous prime-boost regimes allows for the beneficial effects of
BCG to be retained. We have developed an immunisation strategy using BCG as the priming
immunisation and a recombinant MVA (rMVA) as the boost. The antigen selected for inclusion
in the rMVA must be present in all strains of BCG. We have selected Antigen 85A, which forms
part of the immunodominant antigen 85 complex. Although there are numerous candidate
antigens for use in a TB vaccine, antigen 85A has long been considered a leading choice. It
is a major target antigen recognised by T cells from infected individuals and it is
protective as a DNA vaccine in small animals. Importantly, for use in BCG prime-MVA boost
regimes, it is highly conserved amongst all mycobacterial species and is present in all
strains of BCG. In small animals it is a major target of the immune responses induced by BCG
and in humans HLA-A2 restricted CD8 T cells have been found in a high proportion of
BCG-immunised individuals. Antigen 85A is an enzyme, mycolyl transferase, which is involved
in cell wall biosynthesis.
Pre-clinical data Using this BCG prime-MVA85A boost in BALB/c mice induces higher levels of
both antigen specific interferon-gamma (IFN-γ) secreting CD4 T and CD8+ T cells and higher
levels of protection than after BCG alone. This regime has now been further evaluated in the
more sensitive guinea pig aerosol challenge model with very encouraging results. Guinea pigs
vaccinated with BCG, followed by MVA85A, and then further boosted with a second recombinant
viral vector, fowlpox, expressing antigen 85A (FP85A) showed significantly greater
protection against challenge than guinea pigs vaccinated with BCG alone. This regime is also
immunogenic and protective in rhesus macaques
Clinical studies The safety and immunogenicity of this BCG prime-MVA85A boost vaccination
strategy has now been evaluated in a series of small-scale Phase I studies in the UK. MVA85A
was the first candidate TB vaccine in clinical trials anywhere in the world in September
2002, and is currently the only one in clinical trials in Africa . The main immunological
read-out used in these clinical trials is the ex-vivo IFN-γ Elispot assay, which is used to
assess specific T cell responses to tuberculin PPD, antigen 85 complex and pools of
overlapping peptides spanning the length of antigen 85A. The best immunological correlate of
protection in murine and human TB is the secretion of IFN-γ from sensitised T cells.
In the UK, 14 mycobacterially and BCG naïve, healthy volunteers have been vaccinated with 5
x 10^7pfu MVA85A, administered intradermally. We find that MVA85A is safe and well
tolerated. A single vaccination with MVA85A induces remarkably high levels of specific
effector T cell responses (median IFN- γ Elispot response to Antigen 85A summed peptide
pools 1153 spots per million PBMC). In addition, the safety of MVA85A in volunteers
previously vaccinated with BCG has now been demonstrated in 17 volunteers. These 17
volunteers show even higher peak levels of antigen specific T cells (median response 2455
spots per million PBMC) 1 week post-vaccination than those immunized with MVA85A alone.
Perhaps more importantly for the induction of T cell memory, volunteers who have been
previously BCG vaccinated maintain higher levels of antigen specific T cells after MVA85A
for up to 24 weeks after vaccination, when compared to those volunteers vaccinated with
MVA85A alone. In contrast to this viral vector boost, the magnitude of T cell responses seen
after vaccination with a leading protein/adjuvant vaccine (for malaria), RTS,S/AS02, is
around 200 spots per million PBMC.
This series of Phase I studies have also replicated in The Gambia, and the results from The
Gambia are equally promising. In both the UK and The Gambian studies, MVA85A induces 5-10
fold higher immune responses than any other recombinant MVA in clinical trials. The most
likely explanation for this is that the volunteers have some weak pre-existing
anti-mycobacterial immunity induced by exposure to environmental mycobacteria, and this
specific anti-mycobacterial immunity is being boosted by MVA85A. We have some preliminary
data to support this hypothesis, and other groups have also found pre-existing immunity to
environmental mycobacteria in healthy UK adults. Vaccines that are good at boosting
previously primed T cell responses, such as MVA85A, are potentially good candidates for a
post-exposure vaccine designed to boost the immune response and prevent the development of
disease in those latently infected. If the high levels of specific T cells seen after a
single immunisation with MVA85A are attributable to the boosting of pre-existing
environmentally induced responses, then this makes MVA85A an extremely promising candidate
for a boosting vaccine, given as a post-exposure vaccine in latent infection.
The next study, which completed enrolment in the UK in February 2006, assessed the safety
and immunogenicity of MVA85A in healthy volunteers who were latently infected with M.tb.
Twelve latently infected healthy subjects were vaccinated with a single dose of 5 x 10^7pfu
MVA85A. In this study, latent M.tb infection was determined by tuberculin skin testing and
ex-vivo IFN-γ Elispot responses to two M.tb specific antigens, ESAT6 and CFP10. Follow-up
involved detailed radiological and clinical assessment of the safety of this vaccine in M.tb
infected subjects. We found that MVA85A is equally safe and equally immunogenic in this
latently infected population as it is in the population vaccinated with BCG (Sander et al,
unpublished data). We have also conducted a dose finding study looking at two further doses
of MVA85A, 1 x 10^7pfu and 1 x 10^8 pfu. Twelve subjects were vaccinated with each dose. The
preliminary results show the vaccine is significantly more immunogenic at the higher (1 x
10^8 pfu) dose but the immunogenicity of the lower (1 x 10^7 pfu) dose is comparable with
the standard (5 x 10^7pfu) dose.
We have just started enrolment into an HIV study where antiretroviral naïve, HIV infected
adults with a CD4 count greater than 350 are vaccinated with MVA85A. To date, there have
been no safety concerns with this study.
MVA85A is being trialled in a series of Phase I and II studies in the Western Cape province,
South Africa, where the prevalence of tuberculosis is extremely high (annual incidence of
disease ~1%). In August 2005, enrolment commenced into trial 008 and it continued until July
2006. 24 healthy TB naïve and HIV uninfected adults were vaccinated. The preliminary results
of this arm of the trial were presented in Vienna (Hawkridge et al, TB Vaccines for the
World; April 2006) and Paris the vaccine was shown to be safe and highly immunogenic.
Enrolment into the adolescent arm of this study commenced in November 2006 once it was clear
that the day 84 safety results in the adults were satisfactory.
This protocol forms the second part of these age de-escalation studies in South Africa,
which are necessary before we commence a Phase IIb proof-of-concept efficacy trial with
MVA85A in this population in 2008.
;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |